Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014, Article ID 480201, 7 pages
http://dx.doi.org/10.1155/2014/480201
Research Article

Human Paraoxonase-1 Activity Is Related to the Number of CD4+ T-Cells and Is Restored by Antiretroviral Therapy in HIV-1-Infected Individuals

1Laboratory of Genetics and Molecular Hematology (LIM31), University of São Paulo School of Medicine, 05403-000 São Paulo, SP, Brazil
2Research Division, Pró-Sangue Hemocentro de São Paulo Foundation, 05403-000 São Paulo, SP, Brazil
3Department of Clinical Laboratory, Health Sciences Center, Federal University of Santa Catarina, 88040-900 Florianópolis, SC, Brazil
4Clinics of Parasitic and Infectious Diseases, Hospital and Clinics of the University of São Paulo School of Medicine, 05403-000 São Paulo, SP, Brazil
5Lipid Metabolism Laboratory, Heart Institute, University of São Paulo School of Medicine, 05403-000 São Paulo, SP, Brazil

Received 26 September 2013; Revised 30 December 2013; Accepted 14 January 2014; Published 27 February 2014

Academic Editor: Fabrizia Bamonti

Copyright © 2014 Luciana Morganti Ferreira Maselli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. A. Riddler, X. Li, H. Chu et al., “Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy,” HIV Medicine, vol. 8, no. 5, pp. 280–287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. J. H. Stein, L. Komarow, B. R. Cotter et al., “Lipoprotein changes in HIV-infected antiretroviral-naïve individuals after starting antiretroviral therapy: ACTG Study A5152s,” Journal of Clinical Lipidology, vol. 2, no. 6, pp. 464–471, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Negredo, R. Paredes, J. Peraire et al., “Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study,” Antiviral Therapy, vol. 9, no. 6, pp. 889–893, 2004. View at Google Scholar · View at Scopus
  4. X. Wang, H. Chai, Q. Yao, and C. Chen, “Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction,” Journal of Acquired Immune Deficiency Syndromes, vol. 44, no. 5, pp. 493–499, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Y. Hui, “Effects of HIV protease inhibitor therapy on lipid metabolism,” Progress in Lipid Research, vol. 42, no. 2, pp. 81–92, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Wohl, R. Scherzer, S. Heymsfield et al., “The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men,” Journal of Acquired Immune Deficiency Syndromes, vol. 48, no. 1, pp. 44–52, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Parra, C. Alonso-Villaverde, B. Coll et al., “Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection,” Atherosclerosis, vol. 194, no. 1, pp. 175–181, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Aviram and M. Rosenblat, “Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences,” Current Opinion in Lipidology, vol. 16, no. 4, pp. 393–399, 2005. View at Google Scholar · View at Scopus
  9. M. I. Mackness, S. Arrol, C. Abbott, and P. N. Durrington, “Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase,” Atherosclerosis, vol. 104, no. 1-2, pp. 129–135, 1993. View at Google Scholar · View at Scopus
  10. M. Aviram and M. Rosenblat, “Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development,” Free Radical Biology and Medicine, vol. 37, no. 9, pp. 1304–1316, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. M. I. Mackness, P. N. Durrington, and B. Mackness, “The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention,” The American Journal of Cardiovascular Drugs, vol. 4, no. 4, pp. 211–217, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Assmann and J. R. Nofer, “Atheroprotective effects of high-density lipoproteins,” Annual Review of Medicine, vol. 54, pp. 321–341, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Masiá, S. Padilla, E. Bernal et al., “Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients,” Clinical Therapeutics, vol. 29, no. 7, pp. 1448–1455, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. J. L. Ngondi, J. Oben, D. M. Forkah, L. H. Etame, and D. Mbanya, “The effect of different combination therapies on oxidative stress markers in HIV infected patients in Cameroon,” AIDS Research and Therapy, vol. 3, no. 1, article 19, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. S. A. Pereira, J. R. Batuca, U. Caixas et al., “Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients,” British Journal of Clinical Pharmacology, vol. 68, no. 6, pp. 891–897, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. V. le Moing, R. Thiébaut, G. Chêne et al., “Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs,” HIV Medicine, vol. 8, no. 3, pp. 156–163, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Sentí, M. Tomás, M. Fitó et al., “Antioxidant paraoxonase 1 activity in the metabolic syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 11, pp. 5422–5426, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972. View at Google Scholar · View at Scopus
  19. W. P. Castelli, R. D. Abbott, and P. M. McNamara, “Summary estimates of cholesterol used to predict coronary heart disease,” Circulation, vol. 67, no. 4, pp. 730–734, 1983. View at Google Scholar · View at Scopus
  20. J. Millán, X. Pintó, A. Muñoz et al., “Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention,” Vascular Health and Risk Management, vol. 5, pp. 757–765, 2009. View at Google Scholar
  21. S. Parra, J. Marsillach, G. Aragonés et al., “Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients,” Journal of Infectious Diseases, vol. 201, no. 4, pp. 627–634, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M. P. Dubé, S. E. Lipshultz, C. J. Fichtenbaum, R. Greenberg, A. D. Schecter, and S. D. Fisher, “Effects of HIV Infection and Antiretroviral Therapy on the Heart and Vasculature,” Circulation, vol. 118, no. 2, pp. e36–e40, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Savès, P. Morlat, G. Chêne et al., “Prognostic value of plasma markers of immune activation in patients with advanced HIV disease treated by combination antiretroviral therapy,” Clinical Immunology, vol. 99, no. 3, pp. 347–352, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. M. May, J. A. C. Sterne, C. Sabin et al., “Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies,” AIDS, vol. 21, no. 9, pp. 1185–1197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. J. J. Eron, B. Young, D. A. Cooper et al., “Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials,” The Lancet, vol. 375, no. 9712, pp. 396–407, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Alonso-Villaverde, T. Segues, B. Coll-Crespo et al., “High-density lipoprotein concentrations relate to the clinical course of HIV viral load in patients undergoing antiretroviral therapy,” AIDS, vol. 17, no. 8, pp. 1173–1178, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. Z. Mujawar, H. Rose, M. P. Morrow et al., “Human immunodeficiency virus impairs reverse cholesterol transport from macrophages,” PLoS Biology, vol. 4, no. 11, article e365, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. B. J. Ansell, K. E. Watson, A. M. Fogelman, M. Navab, and G. C. Fonarow, “High-density lipoprotein function: recent advances,” Journal of the American College of Cardiology, vol. 46, no. 10, pp. 1792–1798, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. S. A. Pereira, T. Branco, R. M. Côrte-Real et al., “Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients,” British Journal of Clinical Pharmacology, vol. 61, no. 5, pp. 601–604, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. F. J. Torriani, L. Komarow, R. A. Parker et al., “Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy. The ACTG (AIDS Clinical Trials Group) Study 5152s,” Journal of the American College of Cardiology, vol. 52, no. 7, pp. 569–576, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Grunfeld, M. Pang, W. Doerrler, J. K. Shigenaga, P. Jensen, and K. R. Feingold, “Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 74, no. 5, pp. 1045–1052, 1992. View at Publisher · View at Google Scholar · View at Scopus
  32. P. E. Tarr, M. Rotger, and A. Telenti, “Dyslipidemia in HIV-infected individuals: from pharmacogenetics to pharmacogenomics,” Pharmacogenomics, vol. 11, no. 4, pp. 587–594, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. J. da Cunha, L. M. Ferreira Maselli, A. Treitinger et al., “Serum levels of IgG antibodies against oxidized LDL and atherogenic indices in HIV-1-infected patients treated with protease inhibitors,” Clinical Chemistry and Laboratory Medicine, vol. 51, no. 2, pp. 371–378, 2013. View at Google Scholar
  34. S. H. Hsia, D. Pan, P. Berookim, and M. L. Lee, “A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease,” The American Journal of Cardiology, vol. 98, no. 8, pp. 1047–1052, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. V. Estrada, P. Geijo, M. Fuentes-Ferrer et al., “Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort,” BMC Women's Health, vol. 11, article 36, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. R. R. Sankatsing, F. W. Wit, M. Vogel et al., “Increased carotid intima-media thickness in HIV patients treated with protease inhibitors as compared to non-nucleoside reverse transcriptase inhibitors,” Atherosclerosis, vol. 202, no. 2, pp. 589–595, 2009. View at Publisher · View at Google Scholar · View at Scopus